来源:药渡撰文:青晏编辑:未来12月24日,丽珠医药集团(股份代号:1513)发布自愿公告,宣布其控股子公司珠海丽珠单抗与北京鑫康合联合开发的莱康奇塔单抗注射液,已正式向国家药品监督管理局提交上市许可申请,并获受理。这标志着国内自研IL-17A/F双靶点抑制剂在银屑病治疗领域迈出关键一步。一、药品基本情况药物名称:莱康奇塔单抗注射液剂型:注射剂规格:160mg(1.6mL)/瓶注册分类:治疗用...
Source Link来源:药渡撰文:青晏编辑:未来12月24日,丽珠医药集团(股份代号:1513)发布自愿公告,宣布其控股子公司珠海丽珠单抗与北京鑫康合联合开发的莱康奇塔单抗注射液,已正式向国家药品监督管理局提交上市许可申请,并获受理。这标志着国内自研IL-17A/F双靶点抑制剂在银屑病治疗领域迈出关键一步。一、药品基本情况药物名称:莱康奇塔单抗注射液剂型:注射剂规格:160mg(1.6mL)/瓶注册分类:治疗用...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.